Keyphrases
Active Crohn's Disease
12%
Adalimumab
100%
Adalimumab Trough Levels
12%
Between-group
12%
Clinical Factors
12%
Confidence Interval
62%
Crohn's Disease
100%
Endoscopic mucosal
25%
Endoscopic Response
62%
Factor Level
12%
Japan
12%
June 2014
12%
Moderate to Severe
25%
Monotherapy
37%
Mucosal Healing
100%
Multicenter Randomized Controlled Trial
12%
Odds Ratio
62%
P for Trend
12%
Pharmacokinetics
100%
Randomized Controlled Trial
12%
Simple Endoscopic Score for Crohn's Disease
37%
Thiopurines
12%
Trough Level
37%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
100%
Azathioprine
33%
Biological Product
11%
Crohn's Disease
100%
Mercaptopurine
11%
Monotherapy
33%
Pharmacokinetics
100%
Randomized Controlled Trial
22%
Trough Level
44%
Immunology and Microbiology
Adalimumab
100%
Azathioprine
33%
Biological Product
11%
Crohn's Disease
100%
Pharmacokinetics
100%
Neuroscience
Adalimumab
100%
Azathioprine
33%
Mercaptopurine
11%
Pharmacokinetics
100%
Randomized Controlled Trial
22%